The newly allowed claims include subject matter covering methods of using a controlled-release oral dosage form of minocycline to treat acne.
Solodyn has one issued US patent, which expires in 2018, related to the use of the Solodyn unique dissolution rate. Solodyn is available by prescription in 45mg, 90mg and 135mg extended release tablet dosages.
Jonah Shacknai, chairman and CEO of Medicis, said: “We are pleased to announce receipt of this notice of allowance by the US Patent and Trademark Office. This represents an important element of maintaining the Solodyn franchise. These allowed patent claims, when issued, will enhance the intellectual property protection of our Solodyn brand.”